Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply

Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply

Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is an in vivo gene editing program which targets and eliminates covalently closed circular DNA (cccDNA), the sole source of viral replication, leading to sustained loss of pre-genomic RNA (pgRNA), the precursor for hepatitis B virus (HBV) DNA. ELIMINATE-B is designed to be a curative treatment for chronic hepatitis B infection.
Find out what a historical investment in Precision BioSciences Inc would be worth today using our DTIL stock calculator.
Market Capitalisation
$172.51M
Price-earnings ratio
-
Dividend yield
0.00%
Volume
79.73K
High today
$6.42
Low today
$6.19
Open price
$6.25
52-week high
$9.62
52-week low
$3.53
Ready to start your investing journey with Stake?
Open an accountThis is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in DTIL on Stake
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
DTIL related stocks